Sp186
A 34 FEMALE WITH AUTOIMMUNE HEPATITIS WITH FATIGUE AND CHOLESTASIS
Date
May 6, 2023
Explore related products in the following collection:
Society: AGA
This session proposed to cover common GI consults on management of patients with liver disease seen at both community and academic centers. Case based presentations on common scenarios such as elevated liver enzymes, autoimmune hepatitis, drug induced liver injury, acute kidney injury in cirrhosis, portal venous thrombosis in cirrhosis, and jaundice in a patient with alcohol-associated liver disease will outline an approach to diagnosis, discussing differential diagnosis, therapeutic options covering rationale for choosing specific options in different clinical settings. LIVE STREAM SESSION
This session proposed to cover common GI consults on management of patients with liver disease seen at both community and academic centers. Case based presentations on common scenarios such as elevated liver enzymes, autoimmune hepatitis, drug induced liver injury, acute kidney injury in cirrhosis, portal venous thrombosis in cirrhosis, and jaundice in a patient with alcohol-associated liver disease will outline an approach to diagnosis, discussing differential diagnosis, therapeutic options covering rationale for choosing specific options in different clinical settings. LIVE STREAM SESSION
Presenter
Rush University Medical Center
Tracks
Related Products
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF PRA023 AS INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: ARTEMIS-UC, COHORT 1
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
PLACEHOLDER
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
INTRODUCTION
SOCIETY: AGA
PANEL DISCUSSION
This session proposed to cover common GI consults on management of patients with liver disease seen at both community and academic centers…